Same data; Different interpretations

Journal of Clinical Oncology

Volumn 34, Issue 31, 2016, Pages 3729-3732

  Bishal Gyawali, ^a   Prasad, Vinay ^b  

^a Nobel College   (Nepal)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; EVEROLIMUS; ANTINEOPLASTIC AGENT; PACLITAXEL; PROTEIN KINASE INHIBITOR;

BREAST CANCER; DATA ANALYSIS; DOSE DENSIFICATION; HUMAN; LUNG CANCER; NOTE; OVARY CANCER; PRIORITY JOURNAL; BREAST TUMOR; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG APPROVAL; EVIDENCE BASED MEDICINE; FEMALE; LUNG TUMOR; MORTALITY; ONCOLOGY; OVARY TUMOR; REPRODUCIBILITY; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CETUXIMAB; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG APPROVAL; EVEROLIMUS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE INHIBITORS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84993967384     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.2021     Document Type: Note

References (27)

1. Prasad V, Kim C, Burotto M, et al: The strength of association between surrogate end points and survival in oncology: A systematic review of trial-level meta-Analyses. JAMA Intern Med 175:1389-1398, 2015
2. Kim C, Prasad V: Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 175:1992-1994, 2015
3. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
4. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 21:1804-1809, 2010
5. Niho S, Kunitoh H, Nokihara H, et al: Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76:362-367, 2012
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) non-small cell lung cancer 4. 2016. https://www.nccn.org/professionals/physician-gls/f-guidelines.asp
7. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
8. Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917, 2010
9. Pujol JL, Pirker R, Lynch TJ, et al: Meta-Analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 83:211-218, 2014
10. Katsumata N, Yasuda M, Isonishi S, et al: Long-Term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol 14: 1020-1026, 2013
11. Pignata S, Scambia G, Katsaros D, et al: Carboplatin plus paclitaxel once a week versus every 3weeks in patientswith advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396-405, 2014
12. Chan JK, Brady MF, Penson RT, et al: Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374:738-748, 2016
13. Oza AM, Cook AD, Pfisterer J, et al: Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol 16:928-936, 2015
14. du Bois A, Kristensen G, Ray-Coquard I, et al: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 17:78-89, 2016
15. Gyawali B, Shimokata T, Ando Y: Discordance between the results and conclusions of ICON7. Lancet Oncol 16:e478, 2015
16. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
17. du Bois A, Floquet A, Kim JW, et al: Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 32:3374-3382, 2014
18. Aghajanian C, Blank SV, Goff BA, et al: OCEANS: A randomized, doubleblind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045, 2012
19. Monk BJ, Poveda A, Vergote I, et al: Anti-Angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:799-808, 2014
20. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA openlabel randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
21. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ovarian cancer. 2015 https://www.nccn. org/professionals/physician-gls/pdf/ovarian.pdf
22. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
23. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520-529, 2012
24. Turner NC, Ro J, Andre F, et al: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209-219, 2015
25. Miles DW, Dié ras V, Corté s J, et al: First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24:2773-2780, 2013
26. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) breast cancer.2. 2016. https://www.nccn. org/professionals/physician-gls/f-guidelines.asp
27. Kim C, Prasad V: Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs.Mayo Clin Proc 91: 713-725, 2016